NewKerala.com

Key Points

The US Food and Drug Administration (FDA) is currently conducting a routine inspection at Samsung Biologics' facilities in South Korea. This inspection comes amid challenging times for the country's biotech industry, with most companies reporting financial difficulties. The FDA's visit is part of a broader initiative to expand regulatory oversight of international manufacturing facilities. Despite the challenges, Samsung Biologics remains a major global contract development and manufacturing organization (CDMO).

Key Points: FDA Inspects Samsung Biologics Amid Global Biotech Challenges

  • FDA examining Samsung Biologics production facilities in Songdo
  • South Korean biotech sector facing significant financial challenges
  • Unannounced global manufacturing inspections expanding
  • 74% of biotech CEOs report unstable funding conditions
2 min read

US FDA conducts inspection at Samsung Biologics facilities in S. Korea: Report

US FDA conducts routine inspection at Samsung Biologics facilities in South Korea, highlighting global biotech industry scrutiny and challenges

"The visit is part of the FDA's regular inspection - Samsung Biologics Official"

Seoul, May 21

The US Food and Drug Administration (FDA) is currently conducting an on-site inspection of Samsung Biologics' production facilities in South Korea, industry sources said Wednesday.

According to the sources, the FDA launched the inspection at the company's facilities in Songdo, west of Seoul, and is scheduled to continue through Tuesday, Yonhap news agency reported.

Samsung Biologics is South Korea's largest bio-company and a major global contract development and manufacturing organisation (CDMO).

FDA officials reportedly visited the company's third and fourth plants Monday to review operations and safety protocols.

A Samsung Biologics official said the visit is part of the FDA's regular inspection.

Samsung Biologics has advised employees to exercise discretion during the inspection period, including mandatory use of personal protective equipment. It also emphasised professional conduct and communication among employees.

A Samsung Biologics official declined to provide specifics but stated that the inspection is unrelated to the FDA's ongoing pilot program for unannounced foreign facility inspections.

According to the Korea Biotechnology Industry Organisation, the FDA has announced a plan to expand unannounced inspections of foreign manufacturing facilities that produce medical products and food.

The initiative is based on a pilot program currently being tested in India and China and aims to subject overseas facilities to the same level of regulatory oversight as US manufacturers.

Meanwhile, in a survey carried out by the Korea Biotechnology Industry Organisation, more than seven out of 10 South Korean biotech companies are facing financial difficulties, Yonhap reported.

According to the survey, nearly four in 10 biotech companies in the country have considered selling their business.

About 74 per cent of chief executive officers (CEOs) and executives of 136 local biotech companies reported unstable funding conditions.

In addition, 76 per cent said their research and development (R&D) schedules have been disrupted due to funding challenges.

Based on the survey, the bio-organisation proposed 10 policy recommendations to the government aimed at strengthening the country's biotech ecosystem.

These include fostering startups, expanding research and development support, encouraging investment, creating a large-scale commercialisation fund, and easing financial regulations.

- IANS

Share this article:

Reader Comments

R
Rajesh K.
Interesting to see FDA expanding inspections globally. India should take note and ensure our pharma companies maintain world-class standards. We can't afford another quality issue like we saw with some cough syrups last year. 🇮🇳
P
Priya M.
Samsung Biologics is a global leader! This shows how South Korea has built world-class biotech capabilities. India needs to invest more in this sector - we have the talent but lack infrastructure and funding support. Hope our startups are watching 👀
A
Amit S.
The financial struggles mentioned here mirror what many Indian biotech firms face. Our government's PLI scheme is good but needs to reach more small companies. Also, why is FDA testing unannounced inspections first in India and China? Feels targeted.
N
Neha T.
As someone working in Indian pharma, FDA inspections are always stressful but necessary. We should see this as an opportunity to improve rather than criticism. Quality should be non-negotiable when it comes to medicines and biologics. 💊
S
Sanjay V.
The Korean biotech industry's challenges show how tough this sector is. India has potential but needs long-term vision - not just copy-paste policies. Our regulators should work more closely with industry to create practical standards.
K
Kavita R.
Interesting article! But I wish it had more details about what exactly FDA looks for during these inspections. As a pharmacy student, this kind of info would be very helpful for my research on global quality standards.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50